These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 34808009)

  • 1. Prognostic impact of Schlafen 11 in bladder cancer patients treated with platinum-based chemotherapy.
    Taniyama D; Sakamoto N; Takashima T; Takeda M; Pham QT; Ukai S; Maruyama R; Harada K; Babasaki T; Sekino Y; Hayashi T; Sentani K; Pommier Y; Murai J; Yasui W
    Cancer Sci; 2022 Feb; 113(2):784-795. PubMed ID: 34808009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based Chemotherapy.
    Conteduca V; Ku SY; Puca L; Slade M; Fernandez L; Hess J; Bareja R; Vlachostergios PJ; Sigouros M; Mosquera JM; Sboner A; Nanus DM; Elemento O; Dittamore R; Tagawa ST; Beltran H
    Mol Cancer Ther; 2020 May; 19(5):1157-1164. PubMed ID: 32127465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Schlafen 11 predicts response to platinum-based chemotherapy in gastric cancers.
    Takashima T; Taniyama D; Sakamoto N; Yasumoto M; Asai R; Hattori T; Honma R; Thang PQ; Ukai S; Maruyama R; Harada K; Kuraoka K; Tanabe K; Sasaki AT; Ohdan H; Morii E; Murai J; Yasui W
    Br J Cancer; 2021 Jul; 125(1):65-77. PubMed ID: 33785877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs.
    Nogales V; Reinhold WC; Varma S; Martinez-Cardus A; Moutinho C; Moran S; Heyn H; Sebio A; Barnadas A; Pommier Y; Esteller M
    Oncotarget; 2016 Jan; 7(3):3084-97. PubMed ID: 26625211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SLFN11 captures cancer-immunity interactions associated with platinum sensitivity in high-grade serous ovarian cancer.
    Winkler C; King M; Berthe J; Ferraioli D; Garuti A; Grillo F; Rodriguez-Canales J; Ferrando L; Chopin N; Ray-Coquard I; Delpuech O; Rinchai D; Bedognetti D; Ballestrero A; Leo E; Zoppoli G
    JCI Insight; 2021 Sep; 6(18):. PubMed ID: 34549724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SLFN11 and ATR as targets for overcoming cisplatin resistance in ovarian cancer cells.
    König P; Eichhorn JM; Suparman E; Bückreiß N; Cinatl J; Michaelis M; Bendas G
    Biochim Biophys Acta Mol Basis Dis; 2024 Dec; 1870(8):167448. PubMed ID: 39117290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SLFN11 is a BRCA Independent Biomarker for the Response to Platinum-Based Chemotherapy in High-Grade Serous Ovarian Cancer and Clear Cell Ovarian Carcinoma.
    Akashi H; Yachida N; Ueda H; Yamaguchi M; Yamawaki K; Tamura R; Suda K; Ishiguro T; Adachi S; Nagase Y; Ueda Y; Ueda M; Abiko K; Kagabu M; Baba T; Nakaoka H; Enomoto T; Murai J; Yoshihara K
    Mol Cancer Ther; 2024 Jan; 23(1):106-116. PubMed ID: 37717249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triple-marker immunohistochemical assessment of muscle-invasive bladder cancer: Is there prognostic significance?
    Labban M; Najdi J; Mukherji D; Abou-Kheir W; Tabbarah A; El-Hajj A
    Cancer Rep (Hoboken); 2021 Apr; 4(2):e1313. PubMed ID: 33538412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of survivin and HMGA2 as biomarkers for cisplatin resistance in bladder cancer.
    Krafft U; Tschirdewahn S; Hess J; Harke NN; Hadaschik B; Olah C; Krege S; Nyirády P; Szendröi A; Szücs M; Módos O; Székely E; Reis H; Szarvas T
    Urol Oncol; 2019 Nov; 37(11):810.e7-810.e15. PubMed ID: 31053526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Epigenomic Approach to Improving Response to Neoadjuvant Cisplatin Chemotherapy in Bladder Cancer.
    Xylinas E; Hassler MR; Zhuang D; Krzywinski M; Erdem Z; Robinson BD; Elemento O; Clozel T; Shariat SF
    Biomolecules; 2016 Sep; 6(3):. PubMed ID: 27598218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies.
    Murai J; Thomas A; Miettinen M; Pommier Y
    Pharmacol Ther; 2019 Sep; 201():94-102. PubMed ID: 31128155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Schlafen-11 expression is associated with immune signatures and basal-like phenotype in breast cancer.
    Isnaldi E; Ferraioli D; Ferrando L; Brohée S; Ferrando F; Fregatti P; Bedognetti D; Ballestrero A; Zoppoli G
    Breast Cancer Res Treat; 2019 Sep; 177(2):335-343. PubMed ID: 31222709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical analysis of SLFN11 expression uncovers potential non-responders to DNA-damaging agents overlooked by tissue RNA-seq.
    Takashima T; Sakamoto N; Murai J; Taniyama D; Honma R; Ukai S; Maruyama R; Kuraoka K; Rajapakse VN; Pommier Y; Yasui W
    Virchows Arch; 2021 Mar; 478(3):569-579. PubMed ID: 32474729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrated pan-cancer gene expression and drug sensitivity analysis reveals SLFN11 mRNA as a solid tumor biomarker predictive of sensitivity to DNA-damaging chemotherapy.
    Shee K; Wells JD; Jiang A; Miller TW
    PLoS One; 2019; 14(11):e0224267. PubMed ID: 31682620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Schlafen family member 11 indicates favorable prognosis of patients with head and neck cancer following platinum-based chemoradiotherapy.
    Hamada S; Kano S; Murai J; Suzuki T; Tsushima N; Mizumachi T; Suzuki M; Takashima T; Taniyama D; Sakamoto N; Fujioka Y; Ohba Y; Homma A
    Front Oncol; 2022; 12():978875. PubMed ID: 36741698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overcoming Resistance to DNA-Targeted Agents by Epigenetic Activation of Schlafen 11 (
    Tang SW; Thomas A; Murai J; Trepel JB; Bates SE; Rajapakse VN; Pommier Y
    Clin Cancer Res; 2018 Apr; 24(8):1944-1953. PubMed ID: 29391350
    [No Abstract]   [Full Text] [Related]  

  • 17. The first evidence for SLFN11 expression as an independent prognostic factor for patients with esophageal cancer after chemoradiotherapy.
    Kagami T; Yamade M; Suzuki T; Uotani T; Tani S; Hamaya Y; Iwaizumi M; Osawa S; Sugimoto K; Miyajima H; Baba S; Sugimura H; Murai J; Pommier Y; Furuta T
    BMC Cancer; 2020 Nov; 20(1):1123. PubMed ID: 33218331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methylation of SLFN11 is a marker of poor prognosis and cisplatin resistance in colorectal cancer.
    He T; Zhang M; Zheng R; Zheng S; Linghu E; Herman JG; Guo M
    Epigenomics; 2017 Jun; 9(6):849-862. PubMed ID: 28403629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamic expression of Schlafen 11 (SLFN11) in circulating tumour cells as a liquid biomarker in small cell lung cancer.
    Zhang B; Stewart CA; Wang Q; Cardnell RJ; Rocha P; Fujimoto J; Solis Soto LM; Wang R; Novegil V; Ansell P; He L; Fernandez L; Jendrisak A; Gilbertson C; Schonhoft JD; Byun J; Jones J; Anderson AKL; Aparicio A; Tran H; Negrao MV; Zhang J; Wang WL; Wistuba II; Wang J; Wenstrup R; Byers LA; Gay CM
    Br J Cancer; 2022 Aug; 127(3):569-576. PubMed ID: 35440668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. STIP1 Tissue Expression Is Associated with Survival in Chemotherapy-Treated Bladder Cancer Patients.
    Krafft U; Tschirdewahn S; Hess J; Harke NN; Hadaschik BA; Nyirády P; Szendröi A; Szücs M; Módos O; Olah C; Székely E; Reis H; Szarvas T
    Pathol Oncol Res; 2020 Apr; 26(2):1243-1249. PubMed ID: 31250373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.